BRCA2 and CDKN1A-interacting protein is a protein that in humans is encoded by the BCCIPgene.
This gene product was isolated on the basis of its interaction with BRCA2 and p21 proteins. It is an evolutionarily conserved nuclear protein with multiple interacting domains. The N-terminal half shares moderate homology with regions of calmodulin and M-calpain, suggesting that it may also bind calcium. Functional studies indicate that this protein may be an important cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity via p21. Several transcript variants encoding different isoforms have been described for this gene.
^ abLiu J, Yuan Y, Huan J, Shen Z (Apr 2001). "Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2". Oncogene. 20 (3): 336–45. doi:10.1038/sj.onc.1204098. PMID11313963.
^ abOno T, Kitaura H, Ugai H, Murata T, Yokoyama KK, Iguchi-Ariga SM, Ariga H (Oct 2000). "TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase". J Biol Chem. 275 (40): 31145–54. doi:10.1074/jbc.M003031200. PMID10878006.
Coleman RA, Rao P, Fogelsong RJ, Bardes ES (1992). "2-Bromopalmitoyl-CoA and 2-bromopalmitate: promiscuous inhibitors of membrane-bound enzymes". Biochim. Biophys. Acta. 1125 (2): 203–9. doi:10.1016/0005-2760(92)90046-X. PMID1571364.
Machackova E, Damborsky J, Valik D, Foretova L (2002). "Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic". Hum. Mutat. 18 (6): 545. doi:10.1002/humu.1232. PMID11748848.
Armakolas A, Ladopoulou A, Konstantopoulou I, et al. (2002). "BRCA2 gene mutations in Greek patients with familial breast cancer". Hum. Mutat. 19 (1): 81–2. doi:10.1002/humu.9003. PMID11754111.